Cancer Control and Survivorship (CCS) Research Program

摘要-癌症控制和生存 癌症控制和生存（CCS）计划的罗伯特H。卢里综合癌症中心 (LCC)是一个多学科计划，重点是三个具体目标：（1）测量科学：提高 患者报告结局（PRO）的测量、分析和解释;（2）生存率研究： 通过研究生物学、行为学和社会文化决定因素， （3）干预措施的制定和实施：制定和实施有针对性的干预措施， 促进癌症控制，减少癌症和相关疗法的急性和长期影响。该计划是 由来自13个系和3所学校的32名教师组成。同行评审资金总额为 10，236，948美元（直接），其中3，769，564美元来自NCI，6，467，384美元来自其他同行评审来源。期间 2016日历年，共有975名参与者参加了项目研究，其中313人参加了干预研究 研究和662例入组观察性或相关性研究。在本供资期间， 575篇癌症相关出版物，21%代表项目内合作，29%代表 项目间合作，88%代表机构间合作。 在当前的资助期内，CCS计划取得了重大进展，其成员进行了 高影响力研究。例如，CCS成员制定并实施了简要的、经过验证的和 临床相关的PRO指标，以及与健康相关的 生存期间的生活质量（HRQoL）。CCS成员也为我们对神经系统的理解做出了贡献。 使用fMRI技术的化疗毒性作用的底物，记录对质量指标的遵守情况 改善外科肿瘤学的结果，并开发和实施了生育力保护技术， 癌症患者和幸存者。研究还开发了最佳的生存护理流程， 诊所和我们的社区。我们的工作基于测量和干预科学发现 我们采取了积极的社会和心理干预措施，以减少我们社区的癌症负担。LCC提供了重要的 通过提供试点资金和获得共享资源，为CCS计划创造价值。反过来，CCS计划 通过强有力的项目领导、CCS项目会议和演讲者系列、覆盖范围- 相关和转化研究，并通过促进影响LCC流域的合作机会 区LCC和CCS领导层制定了一项战略计划，以指导我们的未来愿景。首要目标 是通过增加深度和广度来进一步加强我们的研究。在接下来的五年里，我们 将扩展到癌症护理提供，精确肿瘤学，儿科生存和传播， 执行科学。我们打算续签我们成功的T32资助;并开发前列腺的PO 1提交材料 癌症和生活方式因素在癌症幸存者。

ABSTRACT – CANCER CONTROL AND SURVIVORSHIP The Cancer Control and Survivorship (CCS) Program of the Robert H. Lurie Comprehensive Cancer Center (LCC) is a multidisciplinary program focusing on three specific aims: (1) Measurement Science: improve the measurement, analysis and interpretation of patient-reported outcomes (PROs); (2) Survivorship Research: improve cancer survivorship by studying biological, behavioral and sociocultural determinants of optimal survivorship; and (3) Intervention Development and Delivery: develop and implement targeted interventions to promote cancer control and reduce acute and long-term effects of cancer and related therapies. The Program is comprised of 32 faculty members from 13 departments and 3 schools. Total peer-reviewed funding is $10,236,948 (direct), with $3,769,564 from the NCI and $6,467,384 from other peer-reviewed sources. During calendar year 2016, a total of 975 participants were enrolled in program studies, with 313 enrolled in intervention studies and 662 enrolled in observational or correlative studies. During the current funding period there were 575 cancer-relevant publications, with 21% representing intra-programmatic collaborations, 29% representing inter-programmatic collaborations, and 88% representing inter-institutional collaborations. Over the current funding period, the CCS Program has made significant gains and its members have conducted high impact studies. For example, CCS members have developed and implemented brief, validated and clinically-relevant PRO measures, and identified contextual and modifiable factors associated with health-related quality of life (HRQoL) during survivorship. CCS members have also contributed to our understanding of neural substrates of the toxic effects of chemotherapy using fMRI techniques, documented adherence to quality metrics to improve surgical oncology outcomes, and developed and implemented fertility preservation techniques for cancer patients and survivors. Studies have also developed optimal processes for survivorship care within our clinics and across our community. Our work is grounded in measurement and intervention science discoveries made and psychosocial interventions to reduce cancer burden in our communities. The LCC provides significant value to the CCS Program by providing pilot funds and access to shared resources. In turn, the CCS program adds value to the LCC with strong program leadership, CCS Program meetings and speaker series, catchment- relevant and translational research, and by promoting collaborative opportunities that impact the LCC catchment area. The LCC and CCS leadership have developed a strategic plan to guide our future vision. The primary goal is to further strengthen our research across our aims by adding depth and breadth. Over the next 5 years, we will expand into cancer care delivery, precision oncology, pediatric survivorship, and dissemination and implementation science. We intend to renew our successful T32 grant; and develop PO1 submissions in prostate cancer and lifestyle factors in cancer survivors.